|
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Clinical research trials and Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer. Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer clinical trial. Participants typically obtain the most effective healthcare available for their Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer  Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
For Condition: recurrent non-small cell lung cancer,stage 3B non-small cell lung cancer,stage 4 non-small cell lung cancer,squamous cell lung cancer,large cell lung cancer,adenosquamous cell lung cancer,adenocarcinoma of the lung
Status: No longer recruiting
Sponsor(s): Tularik ,
Synopsis: RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol. Combining lometrexol with folic acid may be an effective treatment for non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combining lometrexol with folic acid in treating patients who have stage IIIB or stage IV non-small cell lung cancer that has been previously treated.
Details: OBJECTIVES: I. Determine the overall response rate in patients with previously treated stage IIIB or IV non-small cell lung cancer when treated with lometrexol and folic acid. II. Determine the complete response rate, duration of response, and time to progression in patients treated with this regimen. III. Determine the 1-year survival rate and overall survival in patients treated with this regimen. IV. Determine the safety profile of this regimen in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patients receive oral folic acid once daily on days -7 to 6. Patients also receive lometrexol IV over 30-60 seconds on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed up to 2 months after removal from study and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 50-100 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed non-small cell lung cancer (NSCLC) - Stage IIIB or IV [*Squamous cell carcinoma *Adenocarcinoma *Large cell carcinoma *Adenosquamous carcinoma] Progressive disease after receiving 1 cisplatin- or carboplatin-containing regimen for stage IIIB or IV disease Measurable disease - At least 1 lesion at least 1 cm x 1 cm by CT scan either not in a previously irradiated field or showing clear evidence of disease progression after radiation No symptomatic or rapidly increasing, moderate or large amounts of pleural effusion or ascites No prior or concurrent CNS metastases (brain or meningeal) --Prior/Concurrent Therapy-- Biologic therapy: - At least 3 weeks since prior biologic therapy for NSCLC and recovered from acute side effects - Prior treatment with an experimental vaccine allowed - No concurrent routine or prophylactic filgrastim (G-CSF), sargramostim (GM- CSF), or epoetin alfa Chemotherapy: - See Disease Characteristics - At least 3 weeks since prior chemotherapy for NSCLC (6 weeks for mitomycin or nitrosourea) and recovered from acute side effects - Prior adjuvant or neoadjuvant chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: - See Disease Characteristics - Recovered from acute side effects of prior radiotherapy - No prior radiotherapy to 25% or more of bone marrow - No prior whole pelvic irradiation Surgery: At least 3 weeks since prior major surgery and recovered Other: - At least 3 weeks since prior investigational agent - No concurrent proguanil, trimethoprim, co-trimoxazole, or pyrimethamine --Patient Characteristics-- Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: At least 3 months Hematopoietic: - Absolute neutrophil count at least 1,500/mm3* - Platelet count at least 100,000/mm3* - Hemoglobin at least 9.0 g/dL* *Without transfusions or growth factors in the previous 7 days Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) (regardless of liver involvement secondary to tumor) - AST and ALT no greater than 2.5 times ULN (5 times ULN if liver has tumor involvement) Renal: Calculated creatinine clearance at least 60 mL/min using Cockroft and Gault formula Gastrointestinal: - No inflammatory bowel disease - No radiation enteritis - No malabsorption syndrome - No inability to absorb folic acid Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during study - No known untreated vitamin B12 deficiency - HIV negative - No drug abusers - No prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No severe concurrent disease or major comorbidity that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SeanMcCarthy, Study Chair, Tularik
U.S. Oncology Research Inc.
Houston, Texas, 77060
United States
US Oncology - Albany Regional Cancer Center
Albany, New York, 12208
United States
Cancer Care Northwest
Spokane, Washington, 99202
United States
Cancer Centers of Florida (U.S. Oncology)
Orlando, Florida, 32806
United States
Louisiana State University School of Medicine
New Orleans, Louisiana, 70112-2822
United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128
United States
Tyler Cancer Center
Tyler, Texas, 75702
United States
Additional Information:
Study ID Numbers: CDR0000069316; USO-01103,TULA-T064031
Study Start Date: February 2002
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00033722
Other Recurrent Non-Small Cell Lung Cancer Studies:
1. Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer
2. Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer
3. Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
4. Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
5. Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Treating Patients With Stage III Non-small Cell Lung Cancer
Related Studies:
Other recurrent non-small cell lung cancer Clinical Trials
Other Texas Clinical Trials
Other Tyler Clinical Trials
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
